The hypoglycaemic and antihyperglycaemic properties of the aqueous extracts of the leaves of Ageratum conyzoides L. were evaluated in normoglycemic and in streptozotocin-induced diabetic rats, in order to validate its use in folk medicine. Tested animals were given the aqueous extracts of the plant at the doses of 100, 200 and 300mg/kg. These doses were tested also on glucose loaded normal male rats (Oral Glucose Tolerance Test). Of all the doses, the aqueous extracts at 200 and 300mg/kg showed statistically significant hypoglycaemic and antihyperglycaemic activities. For the oral glucose tolerance test, 100mg/kg dose only attenuated significantly the rise of blood glucose in normal fasted rats. Consequently, these results confirmed the hypoglycaemic properties of the leaves of Ageratum conyzoides.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2816573 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Improved glycaemic control in people with type 2 diabetes initiating or switching to IDegAsp in a real-world setting in China.
Diabetes Obes Metab
December 2024
Novo Nordisk India Private Limited, Bangalore, India.
Aims: To investigate glycaemic control in Chinese adults with type 2 diabetes (T2D) initiating, or switching to insulin degludec/insulin aspart (IDegAsp), a co-formulation of basal, and bolus insulin, in a real-world setting.
Materials And Methods: A 20-week, prospective, single-arm, open-label, non-interventional study was conducted in Chinese adults with T2D initiating, or switching to IDegAsp after anti-hyperglycaemic treatment with oral antidiabetic drugs (OADs), other insulins, or glucagon-like peptide-1 receptor agonists. The primary endpoint was a change in HbA from baseline to end of the study; the secondary endpoints included a change in fasting plasma glucose and Diabetes Treatment Satisfaction Questionnaire (DTSQ) score.
Systematic review of guideline recommendations for older and frail adults with type 2 diabetes mellitus.
Age Ageing
November 2024
Faculty of Pharmaceutical Sciences, The University of British Columbia-Vancouver Campus, Vancouver, British Columbia V6T 1Z4, Canada.
Article Synopsis
- Clinical practice guidelines (CPGs) for diabetes management face challenges in older adults due to factors like frailty and multiple health issues.
- * The systematic review analyzed 23 CPGs from the last decade, focusing on HbA1c targets and treatment recommendations for older and frail individuals.
- * Results showed most CPGs recommend stricter HbA1c targets for healthier older adults, while suggesting more lenient targets for frail individuals, though there's variability in pharmacotherapy advice, especially for frail patients.
The peri-operative implications of sodium-glucose co-transporter 2 inhibitors: a narrative review.
Anaesthesia
January 2025
Department of Anaesthesiology, University of Hong Kong, Hong Kong.
Introduction: Sodium-glucose co-transporter 2 inhibitors are a novel class of antihyperglycaemic drugs used in the management of type 2 diabetes, that improve glycaemic control, cardiovascular outcomes and promote weight loss. They are also approved for the treatment of heart failure and chronic kidney disease in patients with or without diabetes. This narrative review discusses the peri-operative effects and implications of sodium-glucose co-transporter 2 inhibitors and gives an overview of current evidence and existing peri-operative guidelines.
View Article and Find Full Text PDFIntense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial.
BMJ
October 2024
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China
Objective: To evaluate whether the intense simplified strategy, which comprises short term intensive insulin therapy (SIIT) followed by subsequent oral antihyperglycaemic regimens, could improve long term glycaemic outcomes in patients with newly diagnosed type 2 diabetes mellitus and severe hyperglycaemia.
Design: Multicentre, open label, randomised trial.
Setting: 15 hospitals in China between December 2017 and December 2020.
Glycaemic outcomes in adults with type 2 diabetes over 34 weeks with the Omnipod® 5 Automated Insulin Delivery System.
Diabetes Obes Metab
January 2025
Insulet Corporation, Acton, Massachusetts, USA.
Aims: The aim was to evaluate the effect of extended use of the Omnipod® 5 Automated Insulin Delivery (AID) System in adults with type 2 diabetes and suboptimal glycaemic control.
Materials And Methods: Following an 8-week single-arm, multicentre, outpatient trial of AID in adults with type 2 diabetes and baseline HbA1c ≥ 8% (≥ 64 mmol/mol), participants were given the opportunity to continue use of the AID system in a 26-week (~6 month) extension phase. The primary safety endpoints were percentage of time with sensor glucose ≥ 250 mg/dL and < 54 mg/dL.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!